{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:41:21Z","timestamp":1760784081728},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T00:00:00Z","timestamp":1447286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00281-015-0543-z","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T10:00:33Z","timestamp":1447322433000},"page":"113-121","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cutaneous dermatomyositis in the era of biologicals"],"prefix":"10.1007","volume":"38","author":[{"given":"Natalie A.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth Ann","family":"Vleugels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P.","family":"Callen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"key":"543_CR1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626\u201336","journal-title":"J Am Acad Dermatol"},{"key":"543_CR2","doi-asserted-by":"crossref","unstructured":"Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, et al. (2015) validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. Epub ahead of print","DOI":"10.1111\/bjd.13915"},{"key":"543_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","volume":"63","author":"I Lundberg","year":"1995","unstructured":"Lundberg I, Brengman JM, Engel AG (1995) Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 63:9\u201316","journal-title":"J Neuroimmunol"},{"key":"543_CR4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s004010051165","volume":"99","author":"S Kuru","year":"2000","unstructured":"Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99:585\u2013588","journal-title":"Acta Neuropathol"},{"key":"543_CR5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11926-996-0007-5","volume":"3","author":"LM Pachman","year":"2001","unstructured":"Pachman LM, Fedczyna TO, Lechman TS, Lutz J (2001) Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep 3:379\u2013386","journal-title":"Curr Rheumatol Rep"},{"key":"543_CR6","first-page":"780","volume":"146","author":"R Klein","year":"2010","unstructured":"Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146:780\u2013784","journal-title":"Arch Dermatol"},{"key":"543_CR7","first-page":"192","volume":"39","author":"G Riolo","year":"2012","unstructured":"Riolo G, Towheed TE (2012) Anti\u2013tumor necrosis factor inhibitor therapy\u2013induced dermatomyositis and fasciitis. J Rheumatol 39:192\u2013194","journal-title":"J Rheumatol"},{"key":"543_CR8","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3899\/jrheum.091413","volume":"37","author":"AM Brunasso","year":"2010","unstructured":"Brunasso AM, Scocco GL, Massone C (2010) Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 37:1549\u20131550","journal-title":"J Rheumatol"},{"key":"543_CR9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamadermatol.2013.5220","volume":"149","author":"SW Liu","year":"2013","unstructured":"Liu SW, Velez NF, Lam C, Femia A, Granter SR, Townsend HB, Vleugels RA (2013) Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol 149:1204\u20131208","journal-title":"JAMA Dermatol"},{"key":"543_CR10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/art.22358","volume":"55","author":"HA Hall","year":"2006","unstructured":"Hall HA, Zimmermann B (2006) Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 55:982\u2013984","journal-title":"Arthritis Rheum"},{"key":"543_CR11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","volume":"29","author":"Y Ishikawa","year":"2010","unstructured":"Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y et al (2010) Etanercept-induced anti-Jo-1-antibody\u2013positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 29:563\u2013566","journal-title":"Clin Rheumatol"},{"key":"543_CR12","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","volume":"42","author":"J Musial","year":"2003","unstructured":"Musial J, Undas A, Celi\u0144ska-Lowenhoff M (2003) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42:1566\u20131568","journal-title":"Rheumatology (Oxford)"},{"key":"543_CR13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/s10165-006-0523-1","volume":"16","author":"Y Urata","year":"2006","unstructured":"Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y (2006) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 16:410\u2013411","journal-title":"Mod Rheumatol"},{"key":"543_CR14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/03009740701281293","volume":"36","author":"E Liozon","year":"2007","unstructured":"Liozon E, Ouattara B, Loustaud-Ratti V, Vidal E (2007) Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol 36:484\u2013486","journal-title":"Scand J Rheumatol"},{"key":"543_CR15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-010-1666-1","volume":"30","author":"Y Ishikawa","year":"2011","unstructured":"Ishikawa Y, Yukawa N, Kawabata D, Ohmura K, Fujii T et al (2011) A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol 30:429\u2013432","journal-title":"Clin Rheumatol"},{"key":"543_CR16","first-page":"240","volume":"48","author":"T Ishiguro","year":"2010","unstructured":"Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y (2010) Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis [in Japanese]. Nihon Kokyuki Gakkai Zasshi 48:240\u2013246","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"543_CR17","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","volume":"54","author":"R Norman","year":"2006","unstructured":"Norman R, Greenberg RG, Jackson JM (2006) Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 54:S139\u2013142","journal-title":"J Am Acad Dermatol"},{"key":"543_CR18","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802\u20131804","journal-title":"J Rheumatol"},{"key":"543_CR19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.22198","volume":"66","author":"KA Rouster-Stevens","year":"2014","unstructured":"Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM (2014) Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res 66:783\u2013787","journal-title":"Arthritis Care Res"},{"key":"543_CR20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"Muscle Study Group","year":"2011","unstructured":"Muscle Study Group (2011) A randomized, pilot study of etanercept in dermatomyositis. Ann Neurol 70:427\u2013436","journal-title":"Ann Neurol"},{"key":"543_CR21","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00296-012-2653-4","volume":"33","author":"D Chen","year":"2013","unstructured":"Chen D, Wang XB, Zhou Y, Zhu XC (2013) Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int 33:2455\u20132458","journal-title":"Rheumatol Int"},{"key":"543_CR22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s10067-006-0325-z","volume":"26","author":"S Dold","year":"2007","unstructured":"Dold S, Justiniano ME, Marquez J, Espinoza LR (2007) Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 26:1186\u20131188","journal-title":"Clin Rheumatol"},{"key":"543_CR23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","volume":"47","author":"P Riley","year":"2008","unstructured":"Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology(Oxford) 47:877\u2013880","journal-title":"Rheumatology(Oxford)"},{"key":"543_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"GJ Hengstman","year":"2008","unstructured":"Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP et al (2008) Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59:159\u2013163","journal-title":"Eur Neurol"},{"key":"543_CR25","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1007\/s00296-011-2220-4","volume":"32","author":"JK Park","year":"2012","unstructured":"Park JK, Yoo HG, Ahn DS, Jeon HS, Yoo WH (2012) Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int 32:3587\u20133590","journal-title":"Rheumatol Int"},{"key":"543_CR26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jbspin.2012.10.012","volume":"80","author":"TC Silva da","year":"2013","unstructured":"da Silva TC, Zon Pretti F, Shinjo SK (2013) Adalimumab in anti-synthetase syndrome. Joint Bone Spine 80:432","journal-title":"Joint Bone Spine"},{"key":"543_CR27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","volume":"134","author":"S Jolles","year":"1998","unstructured":"Jolles S, Hughes J, Whittaker S (1998) Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 134:80\u201386","journal-title":"Arch Dermatol"},{"key":"543_CR28","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1007\/s10875-014-0024-5","volume":"34","author":"MC Dalakas","year":"2014","unstructured":"Dalakas MC (2014) Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol 34:S120\u20136","journal-title":"J Clin Immunol"},{"key":"543_CR29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","volume":"18","author":"E Saito","year":"2008","unstructured":"Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y et al (2008) Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 18:34\u201344","journal-title":"Mod Rheumatol"},{"key":"543_CR30","first-page":"29","volume":"10","author":"I Gottfried","year":"2000","unstructured":"Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B (2000) High dose intravenous immunoglobulin (IVIg) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10:29\u201335","journal-title":"Eur J Dermatol"},{"key":"543_CR31","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"543_CR32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40257-013-0028-6","volume":"14","author":"AN Femia","year":"2013","unstructured":"Femia AN, Vleugels RA, Callen JP (2013) Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Amer J Clin Dermatol 14:291\u2013313","journal-title":"Amer J Clin Dermatol"},{"key":"543_CR33","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/jdv.12223","volume":"28","author":"T Bounfour","year":"2014","unstructured":"Bounfour T, Bouaziz JD, Bezier M, Cordoliani F, Saussine A et al (2014) Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol 28:1150\u20131157","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"543_CR34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","volume":"61","author":"MG Danieli","year":"2002","unstructured":"Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A et al (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis. Ann Rheum Dis 61:37\u201341","journal-title":"Ann Rheum Dis"},{"key":"543_CR35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","volume":"9","author":"MG Danieli","year":"2009","unstructured":"Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A (2009) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimm Rev 9:124\u2013127","journal-title":"Autoimm Rev"},{"key":"543_CR36","first-page":"397","volume":"30","author":"EI Kampylafka","year":"2012","unstructured":"Kampylafka EI, Kosmidis ML, Panagiotakos DB, Dalakas M, Moutsopoulos HM, Tzioufas AG (2012) The effect of intravenous immunoglobulin (IVIg) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol 30:397\u2013401","journal-title":"Clin Exp Rheumatol"},{"key":"543_CR37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","volume":"10","author":"MG Danieli","year":"2011","unstructured":"Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10:144\u2013149","journal-title":"Autoimmun Rev"},{"key":"543_CR38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","volume":"33","author":"MG Danieli","year":"2014","unstructured":"Danieli MG, Moretti R, Gambini S, Paolini L, Gabrielli A (2014) Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol 33:531\u2013536","journal-title":"Clin Rheumatol"},{"key":"543_CR39","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jaad.2008.09.051","volume":"60","author":"Y Penate","year":"2009","unstructured":"Penate Y, Guillermo P, Melwani P, Martel R, Hernandez-Machin B et al (2009) Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol 60:1076\u20131077","journal-title":"J Am Acad Dermatol"},{"key":"543_CR40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971\u2013982","journal-title":"Lancet"},{"key":"543_CR41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601\u2013607","journal-title":"Arthritis Rheum"},{"key":"543_CR42","first-page":"1021","volume":"33","author":"EH Noss","year":"2006","unstructured":"Noss EH, Hausner-Sypek DL, Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33:1021\u20131026","journal-title":"J Rheumatol"},{"key":"543_CR43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.rhu.0000182155.08982.60","volume":"11","author":"N Chiappetta","year":"2005","unstructured":"Chiappetta N, Steier J, Gruber B (2005) Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 11:264\u2013266","journal-title":"J Clin Rheumatol"},{"key":"543_CR44","first-page":"1369","volume":"32","author":"O Lambotte","year":"2005","unstructured":"Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32:1369\u20131370","journal-title":"J Rheumatol"},{"key":"543_CR45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","volume":"56","author":"HV Dinh","year":"2007","unstructured":"Dinh HV, McCormack C, Hall S, Prince HM (2007) Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 56:148\u2013153","journal-title":"J Am Acad Dermatol"},{"key":"543_CR46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jbspin.2007.05.011","volume":"75","author":"Z Touma","year":"2008","unstructured":"Touma Z, Arayssi T, Kibbi L, Masri AF (2008) Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 75:334\u2013337","journal-title":"Joint Bone Spine"},{"key":"543_CR47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143:763\u2013767","journal-title":"Arch Dermatol"},{"key":"543_CR48","first-page":"1230","volume":"35","author":"E Feist","year":"2008","unstructured":"Feist E, Dorner T, Sorensen H, Burmester GR (2008) Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 35:1230\u20131232","journal-title":"J Rheumatol"},{"key":"543_CR49","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","volume":"50","author":"EA Mahler","year":"2011","unstructured":"Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology(Oxford) 50:2206\u20132213","journal-title":"Rheumatology(Oxford)"},{"key":"543_CR50","first-page":"887","volume":"26","author":"SM Sultan","year":"2008","unstructured":"Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G (2008) Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 26:887\u2013893","journal-title":"Clin Exp Rheumatol"},{"key":"543_CR51","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.transproceed.2007.11.072","volume":"40","author":"Z Kaposztas","year":"2008","unstructured":"Kaposztas Z, Etheridge WB, Kahan BD (2008) Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transplant Proc 40:1744\u20131746","journal-title":"Transplant Proc"},{"key":"543_CR52","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00296-010-1458-6","volume":"32","author":"M Haroon","year":"2012","unstructured":"Haroon M, Devlin J (2012) Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int 32:1783\u20131784","journal-title":"Rheumatol Int"},{"key":"543_CR53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CND.0b013e318221259d","volume":"13","author":"N Parziale","year":"2011","unstructured":"Parziale N, Kovacs SC, Thomas CB, Srinivasan J (2011) Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders. J Clin Neuromuscul Dis 13:63\u201367","journal-title":"J Clin Neuromuscul Dis"},{"key":"543_CR54","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","volume":"53","author":"L Unger","year":"2014","unstructured":"Unger L, Kampf S, Luthke K, Aringer M (2014) Rituximab therapy in patients with refratory dermatomyositis or polymyositis: diferential effects in a real-life population. Rheumatology (Oxford) 53:1630\u20131638","journal-title":"Rheumatology (Oxford)"},{"key":"543_CR55","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.22856","volume":"56","author":"MA Cooper","year":"2007","unstructured":"Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ (2007) Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56:3107\u20133111","journal-title":"Arthritis Rheum"},{"key":"543_CR56","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3899\/jrheum.101321","volume":"38","author":"B Bader-Meunier","year":"2011","unstructured":"Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A et al (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 38:1436\u20131440","journal-title":"J Rheumatol"},{"key":"543_CR57","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324","journal-title":"Arthritis Rheum"},{"key":"543_CR58","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66:740\u2013749","journal-title":"Arthritis Rheumatol"},{"key":"543_CR59","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T et al (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371:2537\u20132538","journal-title":"N Engl J Med"},{"key":"543_CR60","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","volume":"73","author":"M Zong","year":"2014","unstructured":"Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J et al (2014) Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 73:913\u2013920","journal-title":"Ann Rheum Dis"},{"key":"543_CR61","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","volume":"160","author":"B Arabshahi","year":"2012","unstructured":"Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160:520\u2013522","journal-title":"J Pediatr"},{"key":"543_CR62","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2015-eular.4518","volume":"74","author":"A Tjarnlund","year":"2015","unstructured":"Tjarnlund A, Dastmalchi M, Mann H, Tomasova Studynkova J, Chura R et al (2015) Abatacept in the treatment of adult dermatomyositis and polymyositis: artermis, a randomized, treatment delayed-start trial. Ann Rheum Dis 74:817","journal-title":"Ann Rheum Dis"},{"key":"543_CR63","first-page":"450","volume":"63","author":"DA Isenberg","year":"1986","unstructured":"Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC (1986) Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 63:450\u2013458","journal-title":"Clin Exp Immunol"},{"key":"543_CR64","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D et al (2005) Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57:664\u2013678","journal-title":"Ann Neurol"},{"key":"543_CR65","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","volume":"31","author":"J Wenzel","year":"2006","unstructured":"Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T et al (2006) Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 31:576\u2013582","journal-title":"Clin Exp Dermatol"},{"key":"543_CR66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","volume":"13","author":"SA Greenberg","year":"2012","unstructured":"Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW et al (2012) Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 13:207\u2013213","journal-title":"Genes Immun"},{"key":"543_CR67","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","volume":"56","author":"RJ Walsh","year":"2007","unstructured":"Walsh RJ, Kong SW, Yao Y, Jalial B, Kiener PA et al (2007) Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 56:3784\u20133792","journal-title":"Arthritis Rheum"},{"key":"543_CR68","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Novitzke J et al (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13:59\u201368","journal-title":"Mol Med"},{"key":"543_CR69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73:256\u2013262","journal-title":"Ann Rheum Dis"},{"key":"543_CR70","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","volume":"70","author":"AP Liao","year":"2011","unstructured":"Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG et al (2011) Interferon \u03b2 is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 70:831\u2013836","journal-title":"Ann Rheum Dis"},{"key":"543_CR71","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","volume":"60","author":"H Bilgic","year":"2009","unstructured":"Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC (2009) Interleukin-6 and type I interferon-regulated genes and chemokines marks disease activity in dermatomyositis. Arthritis Rheum 60:3436\u20133446","journal-title":"Arthritis Rheum"},{"key":"543_CR72","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","volume":"53","author":"M Kondo","year":"2014","unstructured":"Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M (2014) A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 53:1907\u2013908","journal-title":"Rheumatology (Oxford)"},{"key":"543_CR73","unstructured":"Danko K, Vencovsky J, Lundberg IE, Amato AA, Oddis CV et al (2014) The selective sphingosine-1-phosphate receptor 1\/5 modulator siponimod(BAF312) shows beneficial effects in patients with active, treatment refractory polymyositis and dermatomyositis:a phase IIa proof-of-concept, double-blind, randomized trial. American college of rheumatology annual meeting. MA, Boston"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-015-0543-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-015-0543-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-015-0543-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:12:17Z","timestamp":1559038337000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-015-0543-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,12]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s00281-015-0543-z","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,12]]}}}